Merck and Moderna announced Wednesday that a personalized mRNA melanoma drug prevented the cancer from returning in a Phase 3 clinical trial, according to the companies. The treatment is tailored to each patient's tumor.
Merck and Moderna confirmed Wednesday that their experimental mRNA-based melanoma drug succeeded in preventing cancer recurrence in a large Phase 3 trial, a significant milestone in personalized cancer therapy. The announcement follows earlier market movements reported by The Zioneer at 15:04 Jerusalem, when Moderna's stock first nearly doubled on the initial Phase 3 results and then surged more than 110% as investor momentum built. The treatment, developed jointly by the two U.S. drugmakers, is tailored to each patient's tumor and aims to stimulate the immune system to attack melanoma cells. Full efficacy data and regulatory next steps remain pending.
4 developments
Source and signal
- Open-source intake